|
Abbott Laboratories (ABT) DCF Valuation
US | Healthcare | Medical - Devices | NYSE
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Abbott Laboratories (ABT) Bundle
Evaluate Abbott Laboratories' financial outlook like a professional! This ABT DCF Calculator provides pre-filled financial data along with the flexibility to modify revenue growth, WACC, margins, and other essential assumptions to align with your projections.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31,904.0 | 34,608.0 | 43,075.0 | 43,653.0 | 40,109.0 | 42,732.5 | 45,527.7 | 48,505.7 | 51,678.5 | 55,058.8 |
| Revenue Growth, % | 0 | 8.48 | 24.47 | 1.34 | -8.12 | 6.54 | 6.54 | 6.54 | 6.54 | 6.54 |
| EBITDA | 7,771.0 | 8,789.0 | 12,742.0 | 12,380.0 | 10,605.0 | 11,463.8 | 12,213.7 | 13,012.6 | 13,863.8 | 14,770.6 |
| EBITDA, % | 24.36 | 25.4 | 29.58 | 28.36 | 26.44 | 26.83 | 26.83 | 26.83 | 26.83 | 26.83 |
| Depreciation | 3,014.0 | 3,327.0 | 3,538.0 | 3,267.0 | 3,243.0 | 3,661.6 | 3,901.1 | 4,156.3 | 4,428.2 | 4,717.8 |
| Depreciation, % | 9.45 | 9.61 | 8.21 | 7.48 | 8.09 | 8.57 | 8.57 | 8.57 | 8.57 | 8.57 |
| EBIT | 4,757.0 | 5,462.0 | 9,204.0 | 9,113.0 | 7,362.0 | 7,802.2 | 8,312.6 | 8,856.3 | 9,435.6 | 10,052.8 |
| EBIT, % | 14.91 | 15.78 | 21.37 | 20.88 | 18.35 | 18.26 | 18.26 | 18.26 | 18.26 | 18.26 |
| Total Cash | 4,140.0 | 7,148.0 | 10,249.0 | 10,170.0 | 7,279.0 | 8,449.9 | 9,002.6 | 9,591.5 | 10,218.8 | 10,887.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 5,425.0 | 6,414.0 | 6,487.0 | 6,218.0 | 6,565.0 | 6,940.6 | 7,394.5 | 7,878.2 | 8,393.5 | 8,942.6 |
| Account Receivables, % | 17 | 18.53 | 15.06 | 14.24 | 16.37 | 16.24 | 16.24 | 16.24 | 16.24 | 16.24 |
| Inventories | 4,316.0 | 5,012.0 | 5,157.0 | 6,173.0 | 6,570.0 | 6,025.6 | 6,419.8 | 6,839.7 | 7,287.1 | 7,763.7 |
| Inventories, % | 13.53 | 14.48 | 11.97 | 14.14 | 16.38 | 14.1 | 14.1 | 14.1 | 14.1 | 14.1 |
| Accounts Payable | 3,252.0 | 3,946.0 | 4,408.0 | 4,607.0 | 4,295.0 | 4,537.4 | 4,834.2 | 5,150.4 | 5,487.3 | 5,846.2 |
| Accounts Payable, % | 10.19 | 11.4 | 10.23 | 10.55 | 10.71 | 10.62 | 10.62 | 10.62 | 10.62 | 10.62 |
| Capital Expenditure | -1,638.0 | -2,177.0 | -1,885.0 | -1,777.0 | -2,202.0 | -2,167.5 | -2,309.3 | -2,460.4 | -2,621.3 | -2,792.7 |
| Capital Expenditure, % | -5.13 | -6.29 | -4.38 | -4.07 | -5.49 | -5.07 | -5.07 | -5.07 | -5.07 | -5.07 |
| Tax Rate, % | 14.12 | 14.12 | 14.12 | 14.12 | 14.12 | 14.12 | 14.12 | 14.12 | 14.12 | 14.12 |
| EBITAT | 4,302.0 | 4,942.0 | 7,926.1 | 7,606.6 | 6,322.4 | 6,809.4 | 7,254.8 | 7,729.4 | 8,235.0 | 8,773.6 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -811.0 | 5,101.0 | 9,823.1 | 8,548.6 | 6,307.4 | 8,714.7 | 8,295.3 | 8,837.9 | 9,416.0 | 10,031.9 |
| WACC, % | 7.58 | 7.58 | 7.56 | 7.55 | 7.56 | 7.57 | 7.57 | 7.57 | 7.57 | 7.57 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 36,371.1 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | 10,433 | |||||||||
| Terminal Value | 292,482 | |||||||||
| Present Terminal Value | 203,096 | |||||||||
| Enterprise Value | 239,467 | |||||||||
| Net Debt | 8,977 | |||||||||
| Equity Value | 230,490 | |||||||||
| Diluted Shares Outstanding, MM | 1,749 | |||||||||
| Equity Value Per Share | 131.78 |
What You Will Get
- Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Abbott Laboratories’ (ABT) financial data pre-filled to accelerate your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Customizable and Professional: A refined Excel model that adjusts to your valuation requirements.
- Built for Analysts and Investors: Perfect for testing projections, validating strategies, and enhancing efficiency.
Key Features
- Customizable Financial Inputs: Adjust key metrics such as revenue growth, operating margin, and research & development expenses.
- Instant DCF Valuation: Quickly computes intrinsic value, net present value, and other financial outputs.
- High-Precision Analytics: Leverages Abbott's actual financial data for accurate valuation results.
- Effortless Scenario Testing: Easily evaluate various assumptions and analyze different outcomes.
- Efficiency Booster: Streamline the valuation process without the hassle of creating complex models from the ground up.
How It Works
- 1. Access the Template: Download and open the Excel file containing Abbott Laboratories' (ABT) preloaded data.
- 2. Modify Assumptions: Adjust key inputs such as growth rates, WACC, and capital expenditures.
- 3. See Results Immediately: The DCF model automatically calculates intrinsic value and NPV.
- 4. Evaluate Scenarios: Analyze various forecasts to understand different valuation outcomes.
- 5. Present with Assurance: Deliver professional valuation insights to back your decisions.
Why Choose Abbott Laboratories (ABT) Stock Analysis?
- Save Time: No need to analyze financials from scratch – our tools are ready to use.
- Enhance Accuracy: Access to reliable data and analytical models minimizes valuation errors.
- Fully Customizable: Adjust the analysis to match your investment assumptions and forecasts.
- Easy to Understand: Intuitive charts and summaries simplify the interpretation of results.
- Endorsed by Professionals: Crafted for investors who prioritize accuracy and user-friendliness.
Who Should Use Abbott Laboratories (ABT)?
- Investors: Gain insights for informed investment decisions with a comprehensive analysis of Abbott Laboratories (ABT).
- Financial Analysts: Streamline your evaluations using a tailored financial model specific to Abbott Laboratories (ABT).
- Consultants: Easily modify the analysis for client briefings or strategic recommendations focused on Abbott Laboratories (ABT).
- Healthcare Enthusiasts: Enhance your knowledge of the healthcare sector through detailed insights into Abbott Laboratories (ABT).
- Educators and Students: Utilize this resource as a hands-on learning tool in healthcare finance courses.
What the Template Contains
- Preloaded ABT Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.